Search Results

AMPAC Fine Chemicals, an SK pharmteco company, adds additional pharmaceutical development and engineering capabilities with the opening of a new Complex Molecule Chemistry & Engineering Center

Nader Pourhassan, who led CytoDyn for nearly 10 years, was convicted in December 2024 of misleading investors regarding the biotech’s investigational COVID-19 and HIV drug, which artificially inflated its share price.

● CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. ● CANDID-CNS™ distinguishes CNS penetrant stereoisomers at 68% compared to 50% by Pfizer’s CNS MPO. ● Published in the Journal of Chemical Information and Modeling, CANDID-CNS™ presents a breakthrough in AI Drug Discovery by unlocking the potential of bRo5 and stereochemistry to significantly expand the chemical space of small molecules that can be developed into CNS therapeutics.

Clarity on employment terms is essential to protect careers. In this column, Kaye/Bassman’s Michael Pietrack speaks to employment attorney Howard Matalon, JD, partner at OlenderFeldman, on how to evaluate the fine print of an employment agreement.

AMPAC Fine Chemicals (AFC) is pleased to announce that effective today Mr. Chris Conley will assume the added responsibilities as Vice President, Human Resources in addition to his position as Vice President, Safety, Health and Environment (SH&E).

AMPAC Fine Chemicals (AFC) is pleased to announce the promotion of Dr. Jeff Butler to the position of Vice President, Project Management and the expansion of Vice President Larry Zeagler’s position as the Head of AFC’s Operations in Petersburg, Virginia

OrphAI Therapeutics Inc. announced the appointment of Jay S. Fine, Ph.D. to its Board of Directors.